Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Lexeo Therapeutics, Inc. Common Stock

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.  Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research.  Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. 

For more information, please visit www.lexeotx.com.

Sarepta Therapeutics

Woodline Partners

Alexandria Venture Investments

Omega Funds

PBM Capital Group

Invus

Alzheimer's Drug Discovery Foundation

Janus Henderson Investors

Longitude Capital

Lundbeckfonden Ventures

CAM Capital

Verition Fund Management

D1 Capital Partners

Eventide

Gray’s Creek Capital Partners

Intus Capital

Laurion Capital Management

Lexeo Therapeutics

Happy holidays to the team members, friends, family, partners, physicians and patients who have contributed to Lexeo’s work in 2023!

In 2023, Lexeo participated in numerous local events to join forces with patient advocates who are raising awareness about devastating diseases such as #Alzheimer’s, #FriedreichsAtaxia and #ArrhythmogenicCardiomyopathy.
 
Look back on some of our favorite photos from the year with Friedreich's Ataxia Research Alliance (FARA) and Alzheimer's Association®!

We are pleased to announce the FDA has granted Orphan Drug designation and Fast Track designation to LX2020, our #genetherapy candidate designed to treat arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM).

Read the full press release here: https://lnkd.in/eq6wzhin

$LXEO shares began trading on Nasdaq last month.
 
Here's a peek behind the curtain of the biggest highlights from IPO day, ringing the Nasdaq closing bell and our event celebrating the Lexeo team for making this possible!
 
#LexeoListed

Yesterday, we reported our Q3 financial results and operational highlights. Check out the highlights below or read the full press release here: https://bit.ly/3Njy60f

COM:LEXEOTX